Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

115.91 -0.30 (-0.26%)
Official Closing Price Updated: 7:00 PM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,354,459
Open 115.46
Bid (Size) 114.30 (100)
Ask (Size) 116.52 (100)
Prev. Close 116.21
Today's Range 114.30 - 116.60
52wk Range 73.31 - 125.14
Shares Outstanding 2,531,374,696
Dividend Yield 2.93%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the... 
Via MarketMinute
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering... 
Via Finterra
Topics Economy Intellectual Property Lawsuit

Performance

YTD
+8.9%
+8.9%
1 Month
-1.1%
-1.1%
3 Month
+17.1%
+17.1%
6 Month
+36.1%
+36.1%
1 Year
+24.2%
+24.2%

More News

Read More
News headline image
2 Dow Jones Stocks to Research Further and 1 Facing Headwinds
Via StockStory
Topics Stocks
News headline image
1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Undervalued Names Too Cheap to Ignore ↗
Via MarketBeat
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗
Via The Motley Fool
News headline image
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
Via Finterra
Topics Intellectual Property
News headline image
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
Via MarketMinute
Topics Earnings Economy
News headline image
2 High-Flying Stocks With More Upside to Buy and Hold ↗
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
News headline image
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗
Via Stocktwits
Topics Earnings Supply Chain
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier
Via MarketMinute
Topics Economy
News headline image
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
From Merck & Co., Inc
Via Business Wire
News headline image
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
Via The Motley Fool
Topics Lawsuit
News headline image
Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Via MarketMinute
Topics Intellectual Property
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough
Via Finterra
Topics Earnings Economy Intellectual Property

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 115.91
When was Merck & Co last traded?
The last trade of Merck & Co was at 03/12/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 293.41B
How many shares of Merck & Co are outstanding?
Merck & Co has 293B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.